Ligand Pharmaceuticals IncLGND
Price$302.74Intrinsic value$241.3620% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $290.5M+73.8% YoYTTM through 30 Jun 2026
Net Income $197.2MTTM through 30 Jun 2026
Free Cash Flow $131.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin93.7%
EBITDA Margin43.9%
Operating Margin33.6%
Net Margin67.9%

Returns

15.4%ROE
10.0%ROA
18.1%ROIC

Balance Sheet Health

Debt / Equity0.46x
Current Ratio21.00x
Net Debt-$319.4Mnet cash position
Cash & Equivalents$1B

Quality Metrics

Altman Z-Score4.35
Piotroski F-Score5 / 9
FCF Margin45.2%
Rule of 4045.3
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $268.1M
Diluted EPS$9.71TTM
'19'20'21'22'23'24'25
FY2025: $6.13

Dividend

No dividend

Capital Allocation

R&D Spend$41.3M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.